EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma

EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma

EGFRvⅢ is an established target for immunotherapy of glioblastoma (GBM). Current study aims to explore the efficacy of EGFRvⅢ-targeted immunotoxin combined with temozolomide (TMZ) or T cell-engaged bispecific antibody for the treatment of GBM. We generated three rabbit monoclonal antibodies (R1, R2,...

Full description

Bibliographic Details
Main Authors:	Le Huang, Huixia He, Ke Wang, Xuqian Ma, Xin Chen, Wenxin Chen, Xuan Wang, Xiaobing Jiang, Mingqian Feng
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	EGFRvⅢ Glioblastoma Temozolomide Immunotoxin Bispecific antibody
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332222010484

Similar Items

Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells
by: Xingmei Zhang, et al.
Published: (2018-03-01)

EGFRvIII Promotes the Proneural–Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis
by: Zhong-Fang Shi, et al.
Published: (2023-03-01)

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma
by: Justin Choi, et al.
Published: (2022-04-01)

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies
by: Kristina Ellwanger, et al.
Published: (2017-05-01)

Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy
by: Cezary Tręda, et al.
Published: (2023-02-01)

Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model
by: Jin Myung Choi, et al.
Published: (2022-09-01)

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
by: Rui Sun, et al.
Published: (2021-06-01)

Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
by: Emily ePadfield, et al.
Published: (2015-01-01)

Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models
by: You Li, et al.
Published: (2020-08-01)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
by: Irene Appolloni, et al.
Published: (2021-08-01)

Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma
by: Rebecca C Abbott, et al.
Published: (2023-01-01)

Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
by: Maxime Fontanilles, et al.
Published: (2020-04-01)

G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells
by: Meryem H. Cetin, et al.
Published: (2023-01-01)

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
by: Bryan D. Choi, et al.
Published: (2019-11-01)

EGFRvIII Promotes Cell Survival during Endoplasmic Reticulum Stress through a Reticulocalbin 1-Dependent Mechanism
by: Juliana Gomez, et al.
Published: (2021-03-01)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
by: Rebecca C Abbott, et al.
Published: (2021-01-01)

Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth
by: Tsutomu Nakazawa, et al.
Published: (2020-04-01)

A Novel and Highly Selective Epidermal Growth Factor Receptor Inhibitor, SMUZ106, for the Treatment of Glioblastoma
by: Ying Jiang, et al.
Published: (2023-05-01)

Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis
by: Liverana Lauretti, et al.
Published: (2022-04-01)

Phenotypical Flexibility of the EGFRvIII-Positive Glioblastoma Cell Line and the Multidirectional Influence of TGFβ and EGF on These Cells—EGFRvIII Appears as a Weak Oncogene
by: Aneta Włodarczyk, et al.
Published: (2022-10-01)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
by: Zhaohui Wang, et al.
Published: (2023-07-01)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH‐wildtype glioblastoma
by: Nayuta Higa, et al.
Published: (2023-01-01)

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells
by: Raghupathy Vengoji, et al.
Published: (2019-06-01)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01)

Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01)

A Novel Bispecific Immunotoxin Delivered by Human Bone Marrow-Derived Mesenchymal Stem Cells to Target Blood Vessels and Vasculogenic Mimicry of Malignant Gliomas [Retraction]
by: Zhang Y, et al.
Published: (2021-09-01)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
by: Jian Yu, et al.
Published: (2022-07-01)

Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma
by: Rodrigo Ramella Munhoz, et al.
Published: (2013-08-01)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
by: Monique eDontenwill, et al.
Published: (2012-10-01)

Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy
by: Yuan Fu, et al.
Published: (2023-06-01)

Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma
by: Can Lu, et al.
Published: (2022-02-01)

Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide
by: Lu-Ting Kuo, et al.
Published: (2017-01-01)

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma
by: Natalia Di Ianni, et al.
Published: (2021-09-01)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
by: Chun Wang, et al.
Published: (2023-05-01)

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
by: Vidyalakshmi Chandramohan, et al.
Published: (2019-05-01)

Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy
by: Laxmi Dhungel, et al.
Published: (2024-02-01)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
by: Celina Bihan, et al.
Published: (2012-09-01)

Lycorine inhibits glioblastoma multiforme growth through EGFR suppression
by: Jia Shen, et al.
Published: (2018-07-01)

Intragenic <i>EGFR::EGFR</i>.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors
by: Lan Zheng, et al.
Published: (2023-12-01)